We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC
SGMO

Delisted

SGMO was delisted on the 4th of May, 2026.

Back to rankings

184 hedge funds and large institutions have $744M invested in SANGAMO THERAPEUTICS INC in 2019 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 41

23% more call options, than puts

Call options by funds: $14.9M | Put options by funds: $12.1M

1.73% more ownership

Funds ownership: 69.25% → 70.98% (+1.7%)

1% less funds holding

Funds holding: 185 → 184 (-1)

4% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 25

14% less capital invested

Capital invested by funds: $860M → $744M (-$116M)

Holders
184
Holders Change
-1
Holders Change %
-0.54%
% of All Funds
4.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
59
Reduced
41
Closed
25
Calls
$14.9M
Puts
$12.1M
Net Calls
+$2.81M
Net Calls Change
-$7.64M

Top Buyers

Rank Fund Capital Flow
1
MWNA
Marshall Wace North America
New York
+$11.6M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
+$6.07M
3
Jennison Associates
Jennison Associates
New York
+$5.78M
4
Morgan Stanley
Morgan Stanley
New York
+$4.21M
5
WA
Wasatch Advisors
Utah
+$3.36M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$6.28M
2
Deutsche Bank
Deutsche Bank
Germany
-$6.22M
3
State Street
State Street
Massachusetts
-$3.69M
4
SFM
Sphera Funds Management
Israel
-$3.03M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Manhattan
151
First Manhattan
New York
$27K – – –
GHCM
152
Glen Harbor Capital Management
California
$19K – – –
Credit Agricole
153
Credit Agricole
France
$18K – – –
CWM
154
Cranbrook Wealth Management
Michigan
$15K – – –
MCIM
155
Meadow Creek Investment Management
Georgia
$15K – – –
BWP
156
Baldwin Wealth Partners
Massachusetts
$14K – – –
BFEC
157
Benjamin F. Edwards & Company
Missouri
$14K – – –
EP
158
Elkfork Partners
Oregon
$12K – – –
WT
159
Whittier Trust
California
$11K +$8.97K +800 +210%
FDCDDQ
160
Federation des caisses Desjardins du Quebec
Quebec, Canada
$10.9K – – –
RE
161
RBC Europe
United Kingdom
$9.05K – – –
AF
162
Allworth Financial
California
$9K – – –
NCM
163
Nelson Capital Management
California
$9K – – –
Nisa Investment Advisors
164
Nisa Investment Advisors
Missouri
$9K – – –
TAM
165
Tyers Asset Management
Texas
$9K – – –
Daiwa Securities Group
166
Daiwa Securities Group
Japan
$7K – – –
BFC
167
Bedel Financial Consulting
Indiana
$6K – – –
FHA
168
Flagship Harbor Advisors
Massachusetts
$6K – – –
APA
169
American Portfolios Advisors
New York
$5.66K -$3.37K -300 -32%
AIC
170
Ameritas Investment Company
Nebraska
$5K +$5.61K +500 New
MAM
171
Meeder Asset Management
Ohio
$5K +$5.88K +524 New
PNC Financial Services Group
172
PNC Financial Services Group
Pennsylvania
$4K – – –
PCM
173
Prelude Capital Management
New York
$3K -$438 -39 -11%
GEA
174
Glen Eagle Advisors
New Jersey
$2.31K – – –
KBC Group
175
KBC Group
Belgium
$2K -$12.7K -1,130 -87%
5 6
7
8 9

SGMO Hedge Fund Activity: Q3 2019 in Review

184 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2019, worth a combined $744M — down 14% from $860M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of SGMO and 24 opened new positions — a net loss of 1 holder — while 41 trimmed existing stakes and 59 added.

The largest buyer was Marshall Wace North America, opening a new position worth an estimated $11.6M. The largest seller was Renaissance Technologies, cutting an estimated $6.28M.

  • 184 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2019, down from 185 in Q2 2019.
  • Funds reported $744M of SANGAMO THERAPEUTICS INC stock for Q3 2019, down 14% quarter-over-quarter.
  • 24 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2019 and 25 closed out, a net change of -1 holder.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q3 2019 was Marshall Wace North America, an estimated $11.6M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q3 2019 was Renaissance Technologies, an estimated $6.28M sold.

Based on aggregated 13F filings for Q3 2019.